What the FDA labels say about taking them together
Cobicistat and ledipasvir/sofosbuvir
Ledipasvir/sofosbuvir's FDA label of December 26, 2024 names cobicistat in its drug interactions section; the cobicistat label PlainMeds reads does not name ledipasvir/sofosbuvir. The ledipasvir/sofosbuvir label: “… regimen containing tenofovir DF without an HIV protease inhibitor/ritonavir or cobicistat. Refer to VIREAD or TRUVADA prescribing information for recommendations on renal monitoring.”
Check it at the source: the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.); the ledipasvir/sofosbuvir FDA label on DailyMed (effective December 26, 2024, Gilead Sciences, Inc).
What does the cobicistat label say about ledipasvir/sofosbuvir?
Cobicistat's label (effective February 10, 2026) does not name ledipasvir/sofosbuvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed
What does the ledipasvir/sofosbuvir label say about cobicistat?
Ledipasvir/sofosbuvir label, drug interactionsConcomitant Drug Class/Drug Name: Regimens containing tenofovir DF without an HIV protease inhibitor/ ritonavir or cobicistat; Effect on Concentration ↓ = decrease, ↑ = increase: ↑ tenofovir; Clinical Comment: Monitor for tenofovir-associated adverse reactions in patients receiving HARVONI concomitantly with a regimen containing tenofovir DF without an HIV protease inhibitor/ritonavir or cobicistat. Refer to VIREAD or TRUVADA prescribing information for recommendations on renal monitoring.
Source: FDA drug label (Harvoni), Gilead Sciences, Inc, effective December 26, 2024 (SPL set f4ec77e4-bae8-4db0-b3d5-bde09c5fa075), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat | Ledipasvir/sofosbuvir | |
|---|---|---|
| Labeled for | HIV | Hepatitis C |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once